Infection Flashcards
Recommended pre-txp serologic testing
- HIV
- HBV (HBsAg, HBsAb, HBcAB)
- HCV Ab
- CMV IgG
- EBV IgG
- Toxo IgG
- Syphilis
- TB
If Endemic region: Strongyloides IgG, Trypanosoma cruzi serology, Coccidioides serology
HBV: Immune due to natural infection
HBsAb +
HBcAb +
HBsAg -
HBV: Immune due to vaccination
HBsAb +
HBcAb -
HBsAg -
HBV: Active infection (acute or chronic)
HBsAb -
HBcAb +
HBsAg +
IgM will determine if acute (+) or chronic (-)
Recommended HBV prevention in liver txp with donor HBcAb+
Antiviral ppx for recipient: indefinite vs 1 year
Recommended HBV prevention in non-liver txp with donor HBcAb+
Antiviral ppx IF no vaccine or natural immunity; if non-immune consider prophylaxis for up to 1-year
Toxoplasma gondii prophylaxis strategies if donor+ or recipient +
- Bactrim
2. Atovaquone +/- pyrimethamine + leucovorin
Strongyloides prophylaxis strategies if donor+
Ivermectin 200 mcg/kg daily x2 doses
Trypanosoma prophylaxis strategies if donor+ for heart txp
Heart –> avoid dt risk of reactivation
Coccidioidomycosis prophylaxis strategies
Endemic area: Fluc 200 mg daily
Seropositive: Fluc 400 mg daily x6-12 months
Recipient post-txp recommended serologic testing
- HIV
- HBV
- HCV
CMV Preemptive monitoring is appropriate to consider for which groups/organs?
High risk: liver, pancreas, kidney
Mod risk: Kidney, liver, pancreas, heart
Kidney txp peri-operative abx recommendations
Cefazolin
24 hr
Liver txp peri-operative abx recommendations
Zosyn | Unasyn | CTR + amp +/- fluc/mica
24-48 hours
Panc txp peri-operative abx recommendations
Some discrepancies - cefazolin vs Unasyn +/- fluc/mica
24-48 hours
Small bowel txp peri-operative abx recommendations
Vanc + Zosyn + Fluc/Mica
72hr-7d
Heart txp peri-operative abx recommendations
Some discrepancies - cefazolin vs Vanco + CTR/Cefepime
24-48 hours
Delayed chest closure: MRSA, PSA, fungi coverage through chest closure
Lung txp peri-operative abx recommendations
Some discrepancies - cefazolin vs Vanco + anti-PSA beta lactam
48-72 hours (or based on donor pathogens)
If CF: target colonizing organisms
Delayed chest closure: MRSA, PSA, fungi coverage through chest closure
Kidney Txp Candida Ppx
Not routinely recommended
Liver Txp Candida Ppx
Fluc x2-4 weeks for those at risk
Re-op, Re-txp, HD, choledoJ, candida colonization, >40u blood products
Intestine Txp Candida Ppx
Fluc/Mica x4 weeks or until anastomosis has healed
Heart Txp Candida Ppx
Not routinely recommended
Some populations may quality for anti-aspergillus ppx: re-operaion, CMV disease, post txp HD, recent IA
Lung Txp Candida Ppx
Anti-aspergillus (vori/itra) x3–6 months
Pancreas Txp Candida Ppx
Fluc for those at risk
Enteric drainage, thrombosis, pancreatitis
PJP Prophylaxis Strategies
- Bactrim: SS QD or MWF, DS MWF
- Dapsone 50 - 100 mg daily
- Atovaquone 1500 mg daily
- Pentamidine 300 mg monthly
- Clinda + pyrimethamine
Donor Bacteremia or Meningitis Strategies
Tx donor x24-48 hr; recip 7-14d with targeted therapy
HIV: Usual HAART combination consists of:
3 drug regimen:
- NRTI (abacavir, emtricitabine, lamivudine, TAF, TDF, zidovudine)
- NRTI
- INSTI (“-tegravir”) or NNRTI (“virine”) or PI/booster (“-navir”
Which HIV meds have interactions with common txp meds?
- PI/boosters (“-navir”) = CYP inhibitors
2. NNRTIs = CYP3A4 inducer
HCV Pan-genotypic regimens
- Velpatasvir + Sofosbuvir (Epclusa)
2. Glecaprevir/pibrentasvir (Mavyret)
Recommended regimens for kidney or liver txp recipients with HCV-infected grafts (HCV viremic donors)
- Velpatasvir + Sofosbuvir (Epclusa) x12 wk
- Glecaprevir/pibrentasvir (Mavyret) x12 wk
Kidney only: Ledipasvir + sofosbuvir (Harvoni) x12 weeks if genotype 1, 4, 5, 6
Epclusa DDI with common txp meds, PPI, DOAC
Velpatasvir + Sofosbuvir
- Mild P-gp inhibition; minimal DDI with ISN
- PPI: separate by 4 hr bc PPI may reduce HCV DAA exposure
- DOACs: Potential inc exposure of DOAC, monitor
Mavyret DDI with common txp meds, PPI, DOAC
Glecaprevir/pibrentasvir
- Inhibits CYP3A4/P-gp = inc FK levels
- CsA inc glecaprevir levels due to OATB inhibition
[AVOID IN PATIENTS ON CSA >100 MG/D] - PPI: may reduce HCV DAA exposure; limit to omep 20 daily due to lack of data with higher dosages
- DOACS: NO DABIGATRAN [Stupid high AUC}; potential inc in exposure of all other DOACS; monitor
Empiric regimens for nocardia
Imipenem + Bactrim OR amikacin
Other abx with activity: linezolid, minocycline, cipro/moxi, augmentin, macrlides
When to suspect CMV resistane
Persistent viremia or symptoms after 2 weeks of appropriate therapy and total exposure >6 weeks
CMV UL97 Mutation
GCV resistance dt changes in drug phosphorylation
CMV UL54 Mutation
GCV resistance +/- CDV and FOS resistance dt change in DNA polymerase
Itraconazole capsule & liquid: Absorption & administration
Capsule: take with meal or acidic beverage if on acid-reducing tx (requires low gastric pH)
Oral solution: better absorption vs capsule; take on empty stomach
Itraconazole TDM Goals
Prophy: >0.5
Tx: >1-2 mcg/mL (parent + metabolite)
Voriconazole tablet & liquid: Absorption & administration
Take on empty stomach; good BA & not dependent on gastric pH
Voriconazole TDM Goals
1-5.5
Voriconazole: How much dose reduce CNI
FK: dec 66%
CsA: dec 50%
Itraconazole : How much dose reduce CNI
FK: dec 50%
CsA: dec 50%
Posaconazole : How much dose reduce CNI
FK: dec 66%
CsA: dec 25%
Posaconazole TDM Goals
> 1250
Posaconazole tablet & liquid: Absorption & administration
Tablet: take with meal; not dependent on gastric pH
Oral solution: take with food & acidic beverage; divide doses to optimize absorption
Recommended BKV screening after KTxp
Monthly x9 mo, then Q3 month until 2 years
Recommended treatment of asymptomatic bacteriuria
If two consecutive urine samples yield >105of the same uropathogen in the first two months post-transplant, can consider treatment for 5 days
Which respiratory viruses can be treated with ribavirin?
RSV, hMPV, PIV
First line treatment options for latent TB
- INH x9 months
- RIF x4 months
- Weekly INH/Rifapentine x12 doses
When to consider steroids for PJP
Corticosteroids are best administered within 72 h of patient presentation in the setting of hypoxia (pAO2 < 70 mm Hg)
Soliris REMS requirements for providers
- Read HCP materials
- Enroll in the REMS program
- Patient counseling & provide patient safety card
- Report ADEs
OPOs should determine if any of the following occurred within past 30 days to determine risk of HIV, HBV, HCV:
- sex w/ infected person
- men who has sex with men
- sex in exchange for $$$ or drugzzzzz
- drug injection for nonmedical reasons
- sex with a person who has inject drugs for nonmedical reasons
- incarceration for 72+ consecutive hours
- child breastfed by HIV mother
- child born to HIV HBV HCV mother
- unknown medical or social hx
Recommended recipient testing for HIV HBV HCV post-txp
4 - 6 weeks test all recipients using NAT
If OLT: test for HBV NAT at 1 year